Human growth hormone therapy linked with pediatric tibial physeal avulsion fractures

A study conducted at the Hospital for Special Surgery found an increased risk of proximal tibial physeal avulsion fractures in pediatric patients receiving recombinant human growth hormone (rhGH) therapy. The study involved 132 pediatric patients and found that 11% of patients with physeal avulsion fractures were receiving rhGH therapy, compared to none in the control group. There was no significant difference in sports-related injuries between the two groups, and they also had similar rates of required surgery. The findings suggest the need for surgeons to consider this risk when counseling pediatric patients and their families about rhGH therapy.

Source link